A share price of Dyne Therapeutics Inc [DYN] is currently trading at $18.83, up 1.18%. An important factor to consider is whether the stock is rising or falling in short-term value. The DYN shares have gain 3.43% over the last week, with a monthly amount glided 13.91%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Dyne Therapeutics Inc [NASDAQ: DYN] stock has seen the most recent analyst activity on October 10, 2025, when Oppenheimer downgraded its rating to a Perform. Previously, Raymond James upgraded its rating to Strong Buy on August 25, 2025, and kept the price target unchanged to $35. On June 24, 2025, Bernstein initiated with a Mkt Perform rating and assigned a price target of $13 on the stock. Evercore ISI started tracking with a Outperform rating for this stock on May 29, 2025, and assigned it a price target of $46. In a note dated March 12, 2025, BMO Capital Markets initiated an Outperform rating and provided a target price of $50 on this stock.
Dyne Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $6.36 and $35.68. Currently, Wall Street analysts expect the stock to reach $28.67 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $18.83 at the most recent close of the market. An investor can expect a potential return of 52.26% based on the average DYN price forecast.
Analyzing the DYN fundamentals
Gross Profit Margin for this corporation currently stands at -0.39% with Operating Profit Margin at -280.49%, Pretax Profit Margin comes in at -262.65%, and Net Profit Margin reading is -262.65%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -0.64 and Total Capital is -0.64. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.29 points at the first support level, and at 17.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.28, and for the 2nd resistance point, it is at 19.73.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Dyne Therapeutics Inc [NASDAQ:DYN] is 13.47. On the other hand, the Quick Ratio is 13.47, and the Cash Ratio is 11.7.
Transactions by insiders
Recent insider trading involved Cox John, CEO & President, that happened on Sep 05 ’25 when 2640.0 shares were sold. Chief Commercial Officer, Friedl-Naderer Johanna completed a deal on Sep 04 ’25 to sell 894.0 shares. Meanwhile, Chief Commercial Officer Friedl-Naderer Johanna sold 144.0 shares on Sep 05 ’25.
